SRC and breast carcinoma: Low dose anti-estrogens (4-OH tamoxifen, fulvestrant) in ER-α66 negative breast cancer with high expression of ER-α36 were shown to activate Src and MAPK/ERK by phosphorylation and activate Cyclin D1 via the Src/EGFR/STAT5 pathway.